US2005158327A1PendingUtilityA1

Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection

50
Priority: Mar 11, 1999Filed: Mar 14, 2005Published: Jul 21, 2005
Est. expiryMar 11, 2019(expired)· nominal 20-yr term from priority
Inventors:Shyam S. MohapatraAruna K. BeheraHiroto MatsuseMukesh Kumar
A61P 31/12A61P 11/00C12N 2310/11C12N 2320/32C12N 15/1138C12N 15/111
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. Also provided is a method of preventing RSV infection by administering an effective amount of an agent that interferes with the binding of RSV to ICAM-1. A method of preventing RSV infection by administering an effective amount of an agent that down regulates the expression of ICAM-1, thereby decreasing RSV binding to ICAM-1 is also provided. There is provided a method of treating RSV infection by administering an effective amount of an agent for down regulating ICAM-1 expression. A method of blocking RSV-ICAM-1 interaction by administering an effective amount of agents for blocking ICAM sites of binding is provided. Also provided is a compound for blocking RSV-ICAM-1 interaction including an agent for blocking ICAM sites of binding.

Claims

exact text as granted — not AI-modified
1 . A method of treating or preventing a respiratory infection comprising administering an effective amount of an agent to a patient, wherein the agent down-regulates ICAM-1 expression or interferes with ICAM-1 binding sites.  
     
     
         2 . The method according to  claim 1 , wherein the infection is a viral infection.  
     
     
         3 . The method according to  claim 1 , wherein the infection is a respiratory syncytial virus (RSV) infection.  
     
     
         4 . The method according to  claim 1 , wherein the agent comprises an antibody to ICAM-1 or an antisense oligonucleotide for ICAM-1.  
     
     
         5 . The method according to  claim 1 , wherein the infection is a respiratory syncytial virus (RSV) infection, and wherein the agent interferes with the binding of RSV to ICAM-1.  
     
     
         6 . The method according to  claim 5 , wherein ICAM-1 has an RSV-F binding site, and wherein the agent blocks the RSV-F binding site on ICAM-1.  
     
     
         7 . The method according to  claim 1 , wherein the agent comprises an antibody to ICAM-1.  
     
     
         8 . The method according to  claim 1 , wherein the infection is a respiratory syncytial virus (RSV), and wherein the agent comprises an antibody to an RSV epitope.  
     
     
         9 . The method according to  claim 1 , wherein the patient is human.  
     
     
         10 . The method according to  claim 1 , wherein said administering comprises administering the agent to airway epithelial cells.  
     
     
         11 . The method according to  claim 10 , wherein said administering comprises administering the agent orally.  
     
     
         12 . The method according to  claim 1 , wherein said administering comprises administering the agent intranasally.  
     
     
         13 . The method according to  claim 1 , wherein said administering comprises administering the agent by inhalation.  
     
     
         14 . The method according to  claim 1 , wherein said administering comprises injecting the agent.  
     
     
         15 . A composition comprising an agent that down-regulates ICAM-1 expression or interferes with ICAM-1 binding sites.  
     
     
         16 . The composition of  claim 15 , wherein said agent is selected from the group consisting of an antibody to ICAM-1, an antibody to an respiratory syncytial virus (RSV) epitope, and an antisense oligonucleotide for ICAM-1.  
     
     
         17 . The composition of  claim 15 , wherein said agent interferes with the binding of respiratory syncytial virus (RSV) to ICAM-1.  
     
     
         18 . The composition of  claim 15 , wherein said agent comprises an antibody to ICAM-1.  
     
     
         19 . The composition of  claim 15 , wherein said agent comprises an antibody to an RSV epitope.  
     
     
         20 . The composition of  claim 15 , wherein said agent blocks the RSV-F binding site on ICAM-1.

Join the waitlist — get patent alerts

Track US2005158327A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.